INTRODUCTION: Histone deacetylase or HDAC inhibitors are famous for their induction of arrest of cell cycle, apoptosis in various tumors found in man, and the terminal differentiation. JNJ-26481585 is a second-generation, hydroxamic acid derivative of HDAC inhibitor that possesses high effectiveness in halting the growth of tumors. There are various pre-clinical studies that have been performed in order to view the role of this molecule. Still, the research work is going on in order to uncover the hidden truths about this molecule and its advantages. JNJ-26481585 ACTIONS: JNJ-26481585 exhibits anti-leukemic activity, and the activities against the leukemic cells. The research studies show that JNJ-26481585 produces synergistic effect along with decitabine during the control of tumor growth and proliferation. JNJ-26481585 possesses broad spectrum activity against all HDAC enzymes. However, it shows greater potency against two classes of HDAC, i.e. the class I and II. In order to inhibit the enzymes of these classes, JNJ-26481585 is required in minimal amount, i.e. 0.11 and 0.33nM [1]. JNJ-26481585 RESEARCH STUDIES: Various clinical or research studies show that JNJ-26481585 can induce continuous acetylation in HCT116 colon tumors, and hence it can powerfully inhibit the growth of cancer in this region. This molecule can also inhibit the growth of tumors which are dependent upon progesterone and estrogen receptors, MDA-MB-231 breast cancers and K-ras mutant A549 non-small cell lung cancers, etc. [19]. Since all of these effects are produced by JNJ-26481585 with greater potency, it is considered one of the major molecules for inhibiting the cancer growth at various places inside the human body. JNJ-26481585 USES: JNJ-26481585 can be used as a single molecule or in combination with other molecules in order to inhibit the HDAC receptors. It can significantly induce expression of P21 promoter and can perform continuous Histone H3 acetylation in various solid tumors inside the human body. JNJ-26481585 is capable to inhibit completely the growth Ras mutant HCT116 colon cancer; it can also be translated into significant preclinical tumor growth inhibition. These actions are superior to the actions of other molecules like 5-fluorouracil and vorinostat. JNJ-26481585 AGAINST LEUKEMIA: JNJ-26481585 is found effective in various leukemic cells, especially they are found effective against U937 and HL60. The other less sensitive lines of leukemic cells are THP1 and MOLT4 respectively. JNJ-26481585 can significantly induce the concentration-dependent acetylation of Histone H3 and H4 in all leukemic cells. This process is done by certain other mechanisms as well, like with the induction of gama-H2AX. This molecule is associated with the DNA double helix break due the various injurious particles that work against the DNA. JNJ-26481585 AGAINST MONOCLONAL CELLS: JNJ-26481585 also possesses stronger anti-tumor activities against the mononuclear cells that are isolated from peripheral blood film of leukemia patients. The molecule can induce apoptosis and acetylation of H3 and gama-H2AX in the leukemic cells having primary origin with very little effects on mononuclear cells. These actions can only be seen if the molecule is used in high concentration [2 and 3]. CONCLUSION: In a nutshell, JNJ-26481585 is a potent molecule that can work against the leukemic cells and various solid tumors inside the human body. This molecule is preferred over the others due to its properties, actions and less margin for the development of adverse reactions. REFERENCES: 1. J. Arts, A. Marien, P. King, W. Floren, A. Belien and L. Janssen et al., JNJ-26481585: a novel second-generation oral pan-histone deacetylase (HDAC) inhibitor showing broad-spectrum preclinical antitumor activity against solid and haematological malignancies, AACR proceedings (2008). 2.H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O’Brien and J. Cortes et al., Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, Blood 109 (2007), pp. 5257. 3.E. Kaminskas, A.T. Farrell, Y.C. Wang, R. Sridhara and R. Pazdur, FDA drug approval summary: azacytidine (5-azacytidine, Vidaza) for injectable suspension, Oncologist 10 (2005), pp. 176182.
Please Rate this Article 5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
